JP7034068B2 - レプチン受容体を活性化させる抗原結合タンパク質 - Google Patents

レプチン受容体を活性化させる抗原結合タンパク質 Download PDF

Info

Publication number
JP7034068B2
JP7034068B2 JP2018518592A JP2018518592A JP7034068B2 JP 7034068 B2 JP7034068 B2 JP 7034068B2 JP 2018518592 A JP2018518592 A JP 2018518592A JP 2018518592 A JP2018518592 A JP 2018518592A JP 7034068 B2 JP7034068 B2 JP 7034068B2
Authority
JP
Japan
Prior art keywords
lepr
antibody
seq
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018518592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535948A5 (cg-RX-API-DMAC7.html
JP2018535948A (ja
Inventor
ジェスパー グロマダ，
パナイオティス ステーヴィス，
ジュディス アルタレホス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57184864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7034068(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2018535948A publication Critical patent/JP2018535948A/ja
Publication of JP2018535948A5 publication Critical patent/JP2018535948A5/ja
Application granted granted Critical
Publication of JP7034068B2 publication Critical patent/JP7034068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018518592A 2015-10-12 2016-10-11 レプチン受容体を活性化させる抗原結合タンパク質 Active JP7034068B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US62/240,021 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US62/359,757 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US62/375,495 2016-08-16
US201662393143P 2016-09-12 2016-09-12
US62/393,143 2016-09-12
PCT/US2016/056465 WO2017066204A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039405A Division JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2018535948A JP2018535948A (ja) 2018-12-06
JP2018535948A5 JP2018535948A5 (cg-RX-API-DMAC7.html) 2019-11-21
JP7034068B2 true JP7034068B2 (ja) 2022-03-11

Family

ID=57184864

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018518592A Active JP7034068B2 (ja) 2015-10-12 2016-10-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2021039405A Active JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2022169008A Active JP7436603B2 (ja) 2015-10-12 2022-10-21 レプチン受容体を活性化させる抗原結合タンパク質
JP2023202680A Active JP7699191B2 (ja) 2015-10-12 2023-11-30 レプチン受容体を活性化させる抗原結合タンパク質
JP2024018406A Active JP7759417B2 (ja) 2015-10-12 2024-02-09 レプチン受容体を活性化させる抗原結合タンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021039405A Active JP7165225B2 (ja) 2015-10-12 2021-03-11 レプチン受容体を活性化させる抗原結合タンパク質
JP2022169008A Active JP7436603B2 (ja) 2015-10-12 2022-10-21 レプチン受容体を活性化させる抗原結合タンパク質
JP2023202680A Active JP7699191B2 (ja) 2015-10-12 2023-11-30 レプチン受容体を活性化させる抗原結合タンパク質
JP2024018406A Active JP7759417B2 (ja) 2015-10-12 2024-02-09 レプチン受容体を活性化させる抗原結合タンパク質

Country Status (32)

Country Link
US (6) US10023644B2 (cg-RX-API-DMAC7.html)
EP (2) EP3362477B1 (cg-RX-API-DMAC7.html)
JP (5) JP7034068B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180070609A (cg-RX-API-DMAC7.html)
CN (1) CN108368177B (cg-RX-API-DMAC7.html)
AU (2) AU2016338851B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007318A2 (cg-RX-API-DMAC7.html)
CA (1) CA3000215A1 (cg-RX-API-DMAC7.html)
CL (2) CL2018000946A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018003852A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125102T1 (cg-RX-API-DMAC7.html)
DK (1) DK3362477T3 (cg-RX-API-DMAC7.html)
EA (1) EA201890928A1 (cg-RX-API-DMAC7.html)
ES (1) ES2908574T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220426T8 (cg-RX-API-DMAC7.html)
HU (1) HUE058280T2 (cg-RX-API-DMAC7.html)
IL (3) IL316563A (cg-RX-API-DMAC7.html)
LT (1) LT3362477T (cg-RX-API-DMAC7.html)
MX (2) MX2018004531A (cg-RX-API-DMAC7.html)
MY (1) MY187975A (cg-RX-API-DMAC7.html)
PH (1) PH12018500663A1 (cg-RX-API-DMAC7.html)
PL (1) PL3362477T3 (cg-RX-API-DMAC7.html)
PT (1) PT3362477T (cg-RX-API-DMAC7.html)
RS (1) RS63061B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201913432RA (cg-RX-API-DMAC7.html)
SI (1) SI3362477T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200125T1 (cg-RX-API-DMAC7.html)
TW (3) TW202417497A (cg-RX-API-DMAC7.html)
UA (1) UA124419C2 (cg-RX-API-DMAC7.html)
UY (1) UY36942A (cg-RX-API-DMAC7.html)
WO (1) WO2017066204A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801975B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR102563568B1 (ko) 2016-11-08 2023-08-04 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체에 길항하는 항원-결합 단백질
CN115025331B (zh) 2017-05-05 2024-06-14 里珍纳龙药品有限公司 自动注射器和相关使用方法
CA3084385A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
WO2020075417A1 (ja) * 2018-10-11 2020-04-16 住友化学株式会社 プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法
CN113424060B (zh) * 2019-01-31 2024-11-26 美国西门子医学诊断股份有限公司 抗纳洛酮和抗纳曲酮单克隆抗体及其生产和使用方法
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
CN114391022B (zh) * 2019-07-02 2023-12-12 上海科技大学 抗瘦素受体的抗体
KR102863417B1 (ko) 2019-12-03 2025-09-24 마이크론 테크놀로지, 인크. 저장 디바이스를 위한 캐시 아키텍처
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230069969A (ko) * 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
US20240153638A1 (en) 2021-02-22 2024-05-09 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
AR134008A1 (es) 2023-10-02 2025-11-26 Regeneron Pharma Sistema de seguridad de dispositivo de administración de fármaco
JP2025148269A (ja) 2024-03-15 2025-10-07 イーライ リリー アンド カンパニー 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505420A (ja) 1996-01-30 2000-05-09 メドヴェト・サイエンス・プロプライアタリー・リミテッド サイトカインアンタゴニストおよびアゴニスト
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
WO2005056602A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
JP2007536212A (ja) 2003-11-17 2007-12-13 ルートヴィヒ マクシミリアン ウニヴェルジテート レプチンアンタゴニストおよびレプチン定量測定方法
US20150037339A1 (en) 2013-07-30 2015-02-05 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
EP0885299B1 (en) 1996-01-08 2005-10-26 Genentech, Inc. Ob receptor and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
CA2244693A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US20100260772A1 (en) 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
NO2792236T3 (cg-RX-API-DMAC7.html) 2009-07-08 2018-04-14
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
CN103298937B (zh) 2010-11-17 2016-05-25 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
ES2946169T3 (es) 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2013271737A1 (en) 2012-06-05 2015-01-22 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
SG10201701831VA (en) 2012-09-12 2017-05-30 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR102563568B1 (ko) 2016-11-08 2023-08-04 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체에 길항하는 항원-결합 단백질
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
CA3084385A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505420A (ja) 1996-01-30 2000-05-09 メドヴェト・サイエンス・プロプライアタリー・リミテッド サイトカインアンタゴニストおよびアゴニスト
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
JP2007536212A (ja) 2003-11-17 2007-12-13 ルートヴィヒ マクシミリアン ウニヴェルジテート レプチンアンタゴニストおよびレプチン定量測定方法
WO2005056602A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US20150037339A1 (en) 2013-07-30 2015-02-05 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and uses thereof

Also Published As

Publication number Publication date
HRP20220426T1 (hr) 2022-05-27
US12275792B2 (en) 2025-04-15
CA3000215A1 (en) 2017-04-20
IL258448A (en) 2018-05-31
US10618968B2 (en) 2020-04-14
TWI824372B (zh) 2023-12-01
US10023644B2 (en) 2018-07-17
SMT202200125T1 (it) 2022-05-12
HRP20220426T8 (hr) 2022-06-10
JP7436603B2 (ja) 2024-02-21
JP7759417B2 (ja) 2025-10-23
US20200031946A1 (en) 2020-01-30
NZ741097A (en) 2025-06-27
JP2024042114A (ja) 2024-03-27
MY187975A (en) 2021-11-05
US20250051465A1 (en) 2025-02-13
JP7165225B2 (ja) 2022-11-02
EP4071173A1 (en) 2022-10-12
NZ780754A (en) 2025-06-27
EP3362477B1 (en) 2022-01-05
IL258448B1 (en) 2023-04-01
IL316563A (en) 2024-12-01
AU2016338851B2 (en) 2023-08-10
RS63061B1 (sr) 2022-04-29
US20220112293A1 (en) 2022-04-14
PT3362477T (pt) 2022-03-02
KR20180070609A (ko) 2018-06-26
SI3362477T1 (sl) 2022-04-29
WO2017066204A1 (en) 2017-04-20
ES2908574T3 (es) 2022-05-03
JP2021090461A (ja) 2021-06-17
JP2024026230A (ja) 2024-02-28
JP2018535948A (ja) 2018-12-06
US20180282420A1 (en) 2018-10-04
KR20250069979A (ko) 2025-05-20
US20180282421A1 (en) 2018-10-04
CL2018000946A1 (es) 2018-12-14
SG10201913432RA (en) 2020-03-30
NZ780753A (en) 2025-06-27
JP2023002713A (ja) 2023-01-10
LT3362477T (lt) 2022-03-10
IL300961A (en) 2023-04-01
UA124419C2 (uk) 2021-09-15
TWI752920B (zh) 2022-01-21
PL3362477T3 (pl) 2022-05-02
CN108368177B (zh) 2022-05-31
ZA201801975B (en) 2020-07-29
CO2018003852A2 (es) 2018-07-10
TW202216785A (zh) 2022-05-01
IL300961B2 (en) 2025-04-01
BR112018007318A2 (en) 2018-10-23
EA201890928A1 (ru) 2018-09-28
AU2016338851A1 (en) 2018-04-19
IL300961B1 (en) 2024-12-01
CY1125102T1 (el) 2024-02-16
DK3362477T3 (da) 2022-03-07
HK1254862A1 (zh) 2019-07-26
US20170101477A1 (en) 2017-04-13
PH12018500663A1 (en) 2018-10-01
EP3362477A1 (en) 2018-08-22
CN108368177A (zh) 2018-08-03
MX2018004531A (es) 2018-09-12
CL2019001434A1 (es) 2019-10-11
MX2023000738A (es) 2023-02-13
AU2023206125A1 (en) 2023-08-31
HUE058280T2 (hu) 2022-07-28
TW201726737A (zh) 2017-08-01
TW202417497A (zh) 2024-05-01
JP7699191B2 (ja) 2025-06-26
UY36942A (es) 2017-05-31
US10253102B2 (en) 2019-04-09
IL258448B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP7042816B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
AU2014240392A1 (en) Human antibodies to Nav1.7
CN104781280A (zh) 抗前动力蛋白受体(prokr)抗体及其使用
HK40072673A (en) Antigen-binding proteins that activate the leptin receptor
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител
BR122025018407A2 (pt) Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
HK1254862B (en) Antigen-binding proteins that activate the leptin receptor
EA041859B1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211213

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211221

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220301

R150 Certificate of patent or registration of utility model

Ref document number: 7034068

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250